Tamar Polonsky to Secondary Prevention
This is a "connection" page, showing publications Tamar Polonsky has written about Secondary Prevention.
Connection Strength
0.775
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA Cardiol. 2024 Sep 01; 9(9):808-816.
Score: 0.206
-
Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial. BMJ Open. 2024 08 07; 14(8):e078197.
Score: 0.205
-
Highlights in ASCVD Primary Prevention for 2021. J Am Heart Assoc. 2022 07 05; 11(13):e025973.
Score: 0.177
-
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease. J Am Heart Assoc. 2024 Feb 20; 13(4):e026921.
Score: 0.050
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. J Am Heart Assoc. 2023 10 17; 12(20):e030385.
Score: 0.048
-
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. Am Heart J. 2023 10; 264:31-39.
Score: 0.047
-
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021 05 27; 384(21):1981-1990.
Score: 0.041